BMTI: Summary for BioMimetic Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 1:50am EST - Canadian Markets open in 7 hours and 40 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

BioMimetic Therapeutics Inc. (BMTI)

On Feb 9: 11.86 USD

0.32 (2.77%)

MORE ON BMTI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

BioMimetic Therapeutics, Inc. (NGM:BMTI) Delayed quote data

After Hours: 11.86 0.00 (0.00%) as of 4:34pm EST on 02/09/10

Last Trade:	11.86 USD
Trade Time:	Feb 9
Change:	0.32 (2.77%)
Prev Close:	11.54
Open:	11.72
Bid:	11.04 x 100
Ask:	12.52 x 100
1y Target Est:	21.00

Day's Range:	11.68 - 12.12
52wk Range:	6.52 - 15.81
Volume:	40,482
Avg Vol (3m):	88,976.2
Market Cap:	258.44M
P/E (ttm):	N/A
EPS (ttm):	-1.33
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add BMTI to Portfolio

Download Data

HEADLINES

•	How the Brokers Stack Up
	at Barrons.com (Fri, Feb 5)

•	BIOMIMETIC THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Wed, Feb 3)

•	BioMimetic Therapeutics, Inc. Patent Portfolio Further Strengthened
	Business Wire (Mon, Feb 1)

•	BIOMIMETIC THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
	EDGAR Online (Thu, Jan 7)

•	BioMimetic Therapeutics Strengthens its Agreement with Novartis for Exclusive Supply of rhPDGF-BB
	Business Wire (Wed, Jan 6)

•	BIOMIMETIC THERAPEUTICS, INC. Files SEC form 8-K, Other Events
	EDGAR Online (Wed, Dec 23)

•	[$$] 13D Filings
	at Barrons.com (Sat, Dec 12)

•	BioMimetic Therapeutics Ships Augment Bone Graft to Canadian Distributor
	Business Wire (Fri, Dec 11)

•	BIOMIMETIC THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Wed, Dec 9)

•	Novo A/S Implements 10b5-1 Trading Plan for Purchase of Additional BioMimetic Therapeutics Shares
	Business Wire (Tue, Dec 8)

More Headlines for BMTI...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	1.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

BioMimetic Therapeutics, Inc. engages in the development and commercialization of bio-active drug-device combination products for healing musculoskeletal injuries and diseases that include periodontal, orthopedic, spine, and sports injury applicat...

Full Company Profile

Add to Portfolio

Email to a Friend

•